Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus gemcitabine/cisplatin for unresectable advanced biliary tract cancer
ChiCTR2400087017Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in biliary cancer, gallbladder cancer, intrahepatic cholangiocarcinoma (ICC) and 2 more, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
biliary cancergallbladder cancerintrahepatic cholangiocarcinoma (ICC)hilar cholangiocarcinoma (HC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2400087017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087017.